Latest filing published 07 Jul 2022 for Taysha Gene Therapies, Inc., €13k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Suyash Prasad: trading record in brief
Suyash Prasad is a declared insider at 2 companies (senior executive); the most frequent names are Audentes Therapeutics, Inc. and Taysha Gene Therapies, Inc. The record holds 48 filings, for trades running from 27 March 2017 to 6 July 2022.
On the market, this insider has only sold: 28 sales, €3.6M in total. Besides market trades, the filings include 4 share grants and 15 option exercises. In 2022 alone, the filings show no purchases and 5 sales.
The latest filing, published on 7 July 2022, reports an open-market sale of €33k in Taysha Gene Therapies, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Suyash Prasad
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,905 shares@ US$3.510.9% of flowCommon StockSEC:0001209191-22-041455:0
- 12,324 shares@ US$3.810.0026% mcap3.1% of flowCommon StockSEC:0001209191-22-040356:0
- 35,056 shares@ US$23.7492.3% of flowCommon StockSEC:0001209191-21-044563:0
3 of 3 declarations
